Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December

Rhea-AI Summary

Exelixis (NASDAQ: EXEL) announced upcoming participation in several virtual investor conferences throughout November and December 2021. The management team will present at events including:

• BMO Biopharma Spotlight Series on November 8 at 12:10 p.m. ET
• Credit Suisse 30th Annual Virtual Healthcare Conference on November 10 at 1:50 p.m. ET
• Stifel 2021 Healthcare Conference on November 16 at 4:40 p.m. ET
• Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, available on demand
• Evercore ISI 4th Annual HealthConX Virtual Conference on December 1 at 11:45 a.m. ET

Webcast links can be accessed via Exelixis' website.

- Presentations to be webcast on www.exelixis.com -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in November and December of 2021:

• BMO Biopharma Spotlight Series: Oncology: Exelixis is scheduled to present at 12:10 p.m. ET / 9:10 a.m. PT on Monday, November 8.
• Credit Suisse 30^th Annual Virtual Healthcare Conference: Exelixis is scheduled to present at 1:50 p.m. ET / 10:50 a.m. PT on Wednesday, November 10.
• Stifel 2021 Healthcare Conference: Exelixis is scheduled to present at 4:40 p.m. ET / 1:40 p.m. PT on Tuesday, November 16.
• Piper Sandler 33^rd Annual Virtual Healthcare Conference: Exelixis’ presentation session will be available to view on-demand beginning 10:00 a.m. ET / 7:00 a.m. PT on Monday, November 22.
• Evercore ISI 4^th Annual HealthConX Virtual Conference: Exelixis is scheduled to present at 11:45am ET / 8:45am PT on Wednesday, December 1.

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX^® (cabozantinib), COMETRIQ^® (cabozantinib), COTELLIC^® (cobimetinib) and MINNEBRO^® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006038/en/

Investors Contact:

Varant Shirvanian

Sr. Investor Relations Manager

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

What conferences will Exelixis participate in during November and December 2021?

Exelixis will participate in the BMO Biopharma Spotlight Series, Credit Suisse 30th Annual Virtual Healthcare Conference, Stifel 2021 Healthcare Conference, Piper Sandler 33rd Annual Virtual Healthcare Conference, and Evercore ISI 4th Annual HealthConX Virtual Conference.

When is Exelixis scheduled to present at the BMO Biopharma Spotlight Series?

Exelixis is scheduled to present at the BMO Biopharma Spotlight Series on November 8, 2021, at 12:10 p.m. ET.

What time will Exelixis present at the Credit Suisse Virtual Healthcare Conference?

Exelixis will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 10, 2021, at 1:50 p.m. ET.

How can I watch the Exelixis presentations at the investor conferences?

The presentations can be accessed via webcast links on the Exelixis website, and replays will be available for 14 days after the events.

What is the significance of Exelixis presenting at these investor conferences?

Presenting at these conferences allows Exelixis to share updates on their oncology-focused initiatives and products with investors and stakeholders.